Tamoxifen

證據等級: L5

預測適應症: 10 個

Tamoxifen: From Hormone Receptor-Positive Breast Cancer to Mammary Paget Disease

One-Sentence Summary

Tamoxifen is a selective estrogen receptor modulator (SERM) internationally established for the treatment and prevention of hormone receptor-positive breast cancer. The TxGNN model predicts it may also be effective for Mammary Paget Disease, a rare form of breast malignancy. Currently only 1 clinical trial (with low direct relevance) and 13 publications (mostly case reports/reviews) support this direction, and Tamoxifen is not currently marketed in Denmark.

Quick Overview

Item	Content
Original Indication	Hormone receptor-positive breast cancer (per internationally established labeling; no Danish marketing data available)
Predicted New Indication	Mammary Paget Disease
TxGNN Prediction Score	99.69%
Evidence Level	L4
Denmark Market Status	Not marketed (未上市)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, tamoxifen is a SERM that competitively blocks estrogen binding to the estrogen receptor (ER) in breast tissue, and its efficacy in ER-positive breast cancer is well established internationally.

Mammary Paget disease is a rare cutaneous manifestation of breast malignancy that very frequently coexists with an underlying ductal carcinoma in situ (DCIS) or invasive ductal carcinoma, and a subset of these underlying tumours are ER-positive. This shared tumour biology provides a plausible mechanistic rationale for tamoxifen’s activity: where the underlying lesion is hormone receptor-positive, tamoxifen’s antiestrogenic effect could theoretically extend to Paget disease as it does to conventional ER-positive breast cancer.

However, no clinical trial identified in this evidence pack was specifically designed to evaluate tamoxifen for Paget disease itself — the single Phase 3 trial addresses a related but different question (endometrial monitoring in tamoxifen-treated patients, a population that included some Paget’s disease cases), and the supporting literature is dominated by case reports and small cohorts rather than interventional evidence. The mechanistic link should therefore be regarded as a reasonable hypothesis rather than a validated finding.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00002920	Phase 3	Completed	313	Evaluated medroxyprogesterone acetate vs. observation for prevention of endometrial pathology in postmenopausal breast cancer patients (including Paget’s disease of the nipple) treated with tamoxifen. Not a direct efficacy trial of tamoxifen for Paget disease (relevance graded C — low).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1648987	1991	Review	The British Journal of Surgery	Case series of 48 women with Paget’s disease of the nipple; treatments included mastectomy, cone excision, and tamoxifen (1 case).
25759627	2014	Cohort/Meta-analysis	Breast Care (Basel)	Meta-analysis of local recurrence after mastectomy vs. breast-conserving surgery for Paget’s disease; recurrence rates up to 20–40%.
16277886	2005	Cohort	Clinical Breast Cancer	Paget’s disease of the nipple presenting as local recurrence after breast-conservation treatment for early-stage breast cancer.
34463889	2022	Case report	Investigational New Drugs	Successful treatment of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen — direct evidence of tamoxifen activity in a Paget-disease-spectrum tumour.
19112575	2009	Case series	Archives of Gynecology and Obstetrics	Vulvar and breast Paget’s disease with synchronous underlying cancer.
29694313	2018	Case report	Il Giornale di Chirurgia	Paget’s disease of the male breast; notes absence of standard treatment guidelines.
12924421	2003	Case report	Surgery Today	Synchronous bilateral breast cancer with Paget’s disease and invasive ductal carcinoma.
8955252	1996	Case report	The American Surgeon	Paget’s disease of the male breast; review of 32 world-literature cases.
18288984	2008	Review	Current Medicinal Chemistry	Review of pharmacotherapies for bone-loss-associated diseases, including estrogen receptor-modulating therapies; tangential relevance.
25328920	2015	Case report	Quintessence International	Osteonecrosis of the jaw in a patient on raloxifene (a related SERM, not tamoxifen); background relevance only.

Denmark Market Information

Tamoxifen currently has no active marketing authorisation on record for the Danish market (market status: not marketed; 0 authorisations). No Laegemiddelstyrelsen or EMA centralised licence data is available in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-interaction data are not currently available in this evidence pack — resolving this gap (TFDA/Danish label warnings and contraindications) is flagged as a Blocking data gap for safety pre-assessment.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for tamoxifen in mammary Paget disease is currently limited to case reports, small cohorts, and one indirectly-relevant Phase 3 trial (Evidence Level L4) — no dedicated interventional trial has evaluated tamoxifen specifically for this indication. Combined with a Blocking gap in Danish/EU label safety data and the drug’s current absence from the Danish market, the evidence does not yet support proceeding.

To proceed, the following is needed:

Danish/EU SmPC data on warnings, contraindications, and drug interactions (resolves Blocking gap DG001)
Detailed mechanism of action documentation (resolves DG002)
A dedicated prospective study or systematic review specifically evaluating tamoxifen in ER-positive mammary Paget disease
Clarification of the Danish market-entry pathway, given the drug currently holds no marketing authorisation in Denmark
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.